|
Evaluating the correlation between early and late quality-of-life declines using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) after definitive stereotactic body radiotherapy, intensity-modulated radiotherapy, or brachytherapy for prostate cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - ViewRay (I) |
Consulting or Advisory Role - Blue Earth Diagnostics; Boston Scientific; Merck Sharp & Dohme; Mevion Medical Systems |
Research Funding - Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Boston Scientific; Merck Sharp & Dohme |
|
Constantine Anastasios Mantz |
Employment - 21st Century Oncology |
|
|
Research Funding - Augmenix |
Travel, Accommodations, Expenses - Brainlab |
|
|
Consulting or Advisory Role - Augmenix; Boston Scientific |
Research Funding - Augmenix (Inst) |
Travel, Accommodations, Expenses - Boston Scientific |